IceCure Medical Ltd., a developer of minimally-invasive cryoablation technology, has announced the expiration and results of its rights offering, raising aggregate gross proceeds of $10 million. The offering, which was approximately two times over-subscribed, allowed holders of the company's ordinary shares to purchase up to 10 million units at a price of $1.00 per unit. The rights offering was conducted under a registration statement on Form F-1, which was declared effective by the U.S. Securities and Exchange Commission $(SEC.UK)$ on July 9, 2025. Maxim Group LLC served as the dealer-manager for the offering.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。